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Abstract: Over the past 20 years obesity has become a worldwide concern of frightening 
proportion. The World Health Organization estimates that there are over 400 million obese and 
over 1.6 billion overweight adults, a ﬁ  gure which is projected to almost double by 2015. This 
is not a disease restricted to adults – at least 20 million children under the age of 5 years were 
overweight in 2005 (WHO 2006). Overweight and obesity lead to serious health consequences 
including coronary artery disease, stroke, type-2 diabetes, heart failure, dyslipidemia, hyperten-
sion, reproductive and gastrointestinal cancers, gallstones, fatty liver disease, osteoarthritis and 
sleep apnea (Padwal et al 2003).
Modest weight loss in the obese of between 5% and 10% of bodyweight is associated with 
improvements in cardiovascular risk proﬁ  les and reduced incidence of type 2 diabetes (Goldstein 
1992; Avenell et al 2004; Padwal and Majumdar 2007). Orlistat, a gastric and pancreatic lipase 
inhibitor that reduces dietary fat absorption by approximately 30%, has been approved for use for 
around ten years (Zhi et al 1994; Hauptman 2000). There is now a growing body of evidence to 
suggest that Orlistat assists weight loss and that it may also have additional beneﬁ  ts. The aim 
of this review is to provide a brief update on the current literature studying the efﬁ  cacy, safety 
and signiﬁ  cance of the use of Orlistat in clinical practice.
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Introduction
Over the past 20 years obesity has become a worldwide concern of frightening propor-
tion. The World Health Organization estimates that there are over 400 million obese 
and over 1.6 billion overweight adults, a ﬁ  gure which is projected to almost double by 
2015. This is not a disease restricted to adults – at least 20 million children under the 
age of 5 years were overweight in 2005 (WHO 2006). Overweight and obesity lead to 
serious health consequences including coronary artery disease, stroke, type-2 diabetes, 
heart failure, dyslipidemia, hypertension, reproductive and gastrointestinal cancers, 
gallstones, fatty liver disease, osteoarthritis and sleep apnea (Padwal et al 2003).
Modest weight loss in the obese of between 5% and 10% of bodyweight is asso-
ciated with improvements in cardiovascular risk proﬁ  les and reduced incidence of 
type 2 diabetes (Goldstein 1992; Avenell et al 2004; Padwal and Majumdar 2007). 
Orlistat, a gastric and pancreatic lipase inhibitor that reduces dietary fat absorption by 
approximately 30%, has been approved for use for around ten years (Zhi et al 1994; 
Hauptman 2000). There is now a growing body of evidence to suggest that Orlistat 
assists weight loss and that it may also have additional beneﬁ  ts. The aim of this review 
is to provide a brief update on the current literature studying the efﬁ  cacy, safety and 
signiﬁ  cance of the use of Orlistat in clinical practice.
Methods
Search strategy
Randomized controlled trials, reviews and meta-analyses of Orlistat were included 
in an electronic search of MEDLINE (1966–2007) and the Cochrane Register of Vascular Health and Risk Management 2007:3(6) 818
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Controlled Trials (1998–2007). The trials were not limited 
by language of publication. Bibliographies of all identiﬁ  ed 
randomized trials and review articles were reviewed for 
additional studies of interest. Two investigators (BD and 
AD) reviewed all citations retrieved to identify potentially 
relevant information for this review.
Results
Weight loss in adults
Orlistat is associated with a small but signiﬁ  cant weight 
loss of around 3% more than diet alone in overweight and 
obese people (BMI  27). A recent Cochrane meta-analysis 
including eleven randomized controlled trials using 120 mg 
Orlistat three times a day found 2.7 kg (95% CI: 2.3 to 
3.1) or 2.9% (95% CI: 2.3 to 3.4) greater weight loss in the 
Orlistat group when compared to placebo. Pooled results 
showed a larger number of participants in the Orlistat group 
achieved clinically signiﬁ  cant weight loss, with 21% (95% 
CI: 19–24) and 12% (95% CI: 8 to 16) achieving 5% 
and 10% weight loss respectively. There were also greater 
reductions in waist circumference with Orlistat therapy 
compared to placebo with reductions from 0.7 to 3.4 cm 
(P  0.05) (Padwal et al 2003).
The common ﬁ  nding that some patients achieve dra-
matically better weight loss results with Orlistat than 
others has important economic implications. One analysis, 
involving overweight and obese non-diabetics, suggests 
that Orlistat is cost effective only if those achieving at 
least 5% weight loss after 3 months continue with therapy 
(Lacey et al 2005).
Maintenance and attrition rates
An important aspect of any weight management strategy 
is the prevention of weight regain after initial weight 
loss. Although there is no data on long-term weight loss, 
medium term studies show that weight loss is generally 
maintained in patients who continue Orlistat therapy. 
A four year double-blind, randomized, placebo-controlled 
trial with Orlistat including 3304 overweight patients 
(XENDOS study) showed mean weight loss after 4 years 
was signiﬁ  cantly greater with Orlistat (5.8 kg vs 3.0 kg with 
placebo; P  0.001) (Torgerson et al 2004). Furthermore, the 
2003 Cochrane meta-analysis showed that Orlistat-treated 
patients regained a smaller percentage of weight compared 
to placebo-treated patients (P  0.05 for all studies) over 
2 years (Padwal et al 2003).
A recent randomized controlled trial looking speciﬁ  cally 
at Orlistat 120 mg three times a day as a weight maintenance 
treatment after weight loss with very low energy diet (VLED) 
demonstrated significantly reduced weight regain after 
3 years (4.6 kg vs 7 kg, P  0.02) (Richelsen et al 2007).
Taking into account high attrition rates, medium term 
weight maintenance on Orlistat therapy is markedly reduced. 
The Cochrane 2003 meta-analysis found high attrition rates 
ranging from 14% to 52% (average 33%) during the weight 
loss phase of Orlistat trials. In the XENDOS study, intention 
to treat analysis which took into account the 48% attrition 
rate showed a smaller yet signiﬁ  cant weight loss with Orlistat 
(3.6 kg vs 1.4 kg with placebo; P  0.001) over 4 years 
(Torgerson et al 2004).
Pharmacoepidemiological studies seem to indicate that 
attrition rates in clinical practice are even higher (64%–77%) 
and the major causes of cessation of treatment are high cost 
and side effects (Vray et al 2005).
Adolescents
While most literature involves adults, a few studies have 
now assessed the impact of Orlistat induced weight loss 
on adolescents. One 54 week multi-centre trial comparing 
Orlistat (N = 357) to placebo (N = 182) in obese 12 to 16 
year olds showed that BMI decreased in both groups at 12 
weeks and then stabilized in those receiving Orlistat, while 
increasing in the placebo-treated group. At study end, BMI 
had decreased by 0.55 kg/m2 in those treated with Orlistat 
and increased by 0.31 kg/m2 in those in the placebo group 
(P = 0.001). Waist circumference decreased in the Orli-
stat group but increased in the placebo group (P  0.05) 
(Chanoine et al 2005). However, in a 6-month randomized, 
double-blind, placebo-controlled trial involving forty ado-
lescents between 14 and 18, Orlistat did not signiﬁ  cantly 
reduce BMI at 6 months (Maahs et al 2006).
Comorbidities
As previously discussed, a weight loss of 5 to 10 percent can 
signiﬁ  cantly reduce the risk factors for diabetes (Knowler 
et al 2002) and cardiovascular disease in high risk patients 
(Douketis et al 2005). Orlistat has been shown to be safe and 
more effective than diet alone in modifying some of the risk 
of coronary artery disease (Lindgarde 2000). Independent of 
weight loss, it is important to look at the effect of Orlistat on 
obesity-related co morbidities.
Type 2 diabetes mellitus
A 2005 Cochrane meta-analysis involving 22 RCTs exam-
ining the beneﬁ  ts of pharmacotherapy for weight loss in 
type-2 diabetes provides evidence that Orlistat can achieve Vascular Health and Risk Management 2007:3(6) 819
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modest but statistically signiﬁ  cant short term weight loss 
when used as a primary weight reduction strategy among 
adults with type 2 diabetes. Pooled data on Orlistat over all 
follow-up periods demonstrated a loss of 2.0kg (95% CI: 
1.3 to 2.8). Pooled reduction for HbA1c was 0.5% (95% 
CI: 0.3 to 0.6) with follow-up between 24 and 57 weeks 
(Norris et al 2005).
Over four years of treatment with Orlistat in the 
XENDOS study, the risk of developing diabetes was found 
to be 37.3% lower compared to placebo (P = 0.0032) 
(Torgerson et al 2004). In the 21% of subjects that had 
impaired glucose tolerance at baseline, the incidence of 
diabetes over the 4 years was decreased by 45.0% with 
Orlistat therapy. This ﬁ  nding has been supported by a more 
recent RCT which showed that the incidence of new type-2 
diabetes was signiﬁ  cantly decreased in patients using Orli-
stat for weight maintenance after initial weight loss (8/153 
new cases type-2 diabetes vs 17/156 cases, P = 0.041) 
(Richelsen et al 2007).
Hypertension and dyslipidemia
Several meta-analyses have shown modest improve-
ments in blood pressure and serum cholesterol in patients 
taking Orlistat.
The 2003 Cochrane meta-analysis showed a signiﬁ  -
cant net decrease in systolic blood pressure in the Orlistat 
group of 1.8 mmHg (95% CI: 0.9 to 2.6), and diastolic BP 
1.6 mmHg (95% CI: 0.7 to 2.4). There were also greater 
reductions in total cholesterol levels 0.33 mmol/L (95% 
CI: 0.28 mmol/L to 0.38 mmol/L) and LDL 0.27 mmol/L 
(95% CI: 0.22 to 0.31). No clinically signiﬁ  cant effects on 
triglycerides or HDL cholesterol were observed (Padwal 
et al 2003). These changes seem to represent an effect 
of Orlistat on lipid malabsorption rather than an effect 
of weight loss alone (Dixon and O’Brien 2001, 2002; 
Mittendorfer et al 2001).
A more recent review of 28 RCTs comparing Orlistat to 
placebo for 6 months supported this data, showing a signiﬁ  -
cant decrease in total cholesterol 0.3 mmol/L (0.57 to 0.28) 
and LDL 0.34 mmol/L (0.36 to 0.32) both P values 0.001. 
Smaller decreases were seen in serum triglycerides 
0.08 mmol/L (0.1 to 0.06, P  0.001) and HDL 0.06 (0.011 
to 0.01), p = 0.02 (Hutton and Fergusson 2004).
The 2005 Cochrane meta-analysis involving type 2 
diabetics also showed that Orlistat was associated with sta-
tistically signiﬁ  cant improvements in total cholesterol, LDL, 
and triglycerides that were sustained at 52 weeks follow up 
(Norris et al 2005).
Other
Other obesity-related co morbidities which have been studied 
include non alcoholic fatty liver disease and disorders of 
menstrual cycle. A recent RCT involving 44 patients with 
NAFLD showed that Orlistat improves serum ALT levels 
and steatosis on ultrasound in NAFLD patients. The authors 
argue that this effect is beyond that expected from the weight 
reduction alone (Zelber-Sagi et al 2006). There is limited 
evidence to suggest that Orlistat may be effective in the treat-
ment of women with obesity and menstrual cycle disorders 
(Totoian et al 2006).
Adverse effects
As a result of its mode of action, the predominant adverse 
effects of Orlistat occur directly or indirectly via the gastro-
intestinal tract. The bioavailability of Orlistat is less than 
1% (due to low systemic absorption and high ﬁ  rst-pass 
metabolism) (McNeely and Benﬁ  eld 1998), and thus direct 
systemic side effects are less common than with other anti-
obesity medications.
The most commonly reported adverse effects of Orlistat 
include steatorrhoea, bloating, oily spotting, fecal urgency 
and fecal incontinence. The percentage of patients expe-
riencing at least one of these side effects appears to be 
around 16% to 40% (Padwal et al 2003). Perhaps the most 
psychologically disturbing side effect, fecal incontinence 
is found in around 7% of patients. There is some concern 
that Orlistat may lower the absorption of the fat soluble 
vitamins A, D, E and K (McNeely and Benﬁ  eld 1998; 
Sjostrom et al 1998; McDufﬁ  e et al 2002). A RCT inves-
tigating the impact of Orlistat on vitamin D absorption, 
bone turnover and bone density found that Orlistat induces 
a relative increase in bone turnover and a net resorption 
of bone, possibly due to malabsorption of vitamin D and 
calcium (Gotfredsen et al 2001). However, the authors 
argue that these changes can be explained by weight loss 
itself. The XENDOS study showed reductions in all fat 
soluble vitamins except vitamin D. Signiﬁ  cant numbers of 
patients using Orlistat over a prolonged period will need 
multivitamin supplements containing fat-soluble vitamins 
(Sjostrom et al 1998; Finer et al 2000). Patients should be 
advised to take them at least 2 hours before or after the 
administration of Orlistat (Orlistat: 2007).
There is some concern that Orlistat may be associated 
with increased risk of colon cancer. Recent preliminary 
research on rats shows an association with Orlistat and 
increases in colonic preneoplastic markers (Garcia et al 
2006). Further research in humans is required. The increased Vascular Health and Risk Management 2007:3(6) 820
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presentation for free fatty acids to the lower gastrointestinal 
tract, produced by combining a lipase inhibitor with a fatty 
diet, is thought to increase oxalate absorption and thus 
heighten risk of kidney stones and renal impairment (Ferraz 
et al 2004; Singh et al 2007).
Drug interactions
As vitamin K absorption may be decreased, warfarin anti-
coagulation may be potentiated during Orlistat therapy 
(MacWalter et al 2003). Therefore, patients stabilised on 
warfarin who commence Orlistat should be monitored for 
changes in INR. Other potential drug interactions include a 
reduction in the absorption of amiodarone (Zhi et al 2003) 
and cyclosporine (Zhi et al 2002).
Conclusion
There are consistent data showing that Orlistat provides a 
modest yet signiﬁ  cant amount of weight loss of around 3% 
more than diet alone in overweight and obese adults. This 
weight loss appears to be maintained in the medium term in 
patients who continue therapy. As with any therapy, some 
patients tend to achieve better results than others. While 
weight loss of greater than 5% is generally considered clini-
cally signiﬁ  cant and may guide patient selection for long-term 
treatment, the beneﬁ  t of lower levels of weight loss in those 
with comorbidities should not be underestimated.
Importantly, Orlistat has been shown to improve gly-
caemic control in type-2 diabetes and reduce the risk of 
developing diabetes in overweight and obese individuals 
with impaired glucose tolerance. It has also been linked to 
small improvements in blood pressure and lower cholesterol 
measurements than expected for the level of weight loss. 
Initial evidence also indicates that Orlistat may be useful 
in the management of NAFLD, menstrual dysfunction and 
overweight and obesity in adolescents.
An important distinction however, is whether the rela-
tively small effects of Orlistat on predictors of cardiovascular 
risk, such as HbA1c, blood pressure and cholesterol, are use-
ful surrogate end points as there is no data on cardiovascular 
morbidity or mortality. High attrition rates call into question 
the tolerability, efﬁ  cacy and cost of Orlistat in clinical prac-
tice, as does the lack of long-term safety data.
Given the lack of efﬁ  cacious non-surgical treatments for 
overweight and obesity, Orlistat does have a place in cur-
rent clinical practice. Where modest weight loss will beneﬁ  t 
those with obesity comorbidity, the addition of Orlistat to 
a program of lifestyle change, diet and physical activity, 
should be considered.
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